| Literature DB >> 31073271 |
Nobuyuki Mishima1,2, Samuel K Jemu3, Tomoaki Kuroda1,2, Koichiro Tabuchi1,2, Andrew W Darcy1, Takaki Shimono1, Pheophet Lamaningao1, Mari Miyake1, Seiji Kanda1, Susan Ng'ambi4, Yoshihiro Komai5, Hirofumi Maeba6, Hiroyuki Amano1, Toshimasa Nishiyama1,2.
Abstract
BACKGROUND: In Malawi, hematobium schistosomiasis is highly endemic. According to previous studies, countermeasures have been conducted mainly in school-aged children. In this study, we focused on the age groups, which are assumed to be major labor force generation. Hematobium schistosomiasis is supposed to be related to occupational activities in schistosome-endemic countries because of its infectious route. We chronologically followed the transition of schistosome egg-positive prevalence before and after mass drug administration of praziquantel (MDA) by using a urine filtering examination. We also analyzed the effectiveness of urine reagent strips from the cost perspective.Entities:
Keywords: Economic growth; Hematobium schistosomiasis; Labor health management; Malawi; Occupational risk; Urine reagent strips
Year: 2019 PMID: 31073271 PMCID: PMC6498665 DOI: 10.1186/s41182-019-0155-8
Source DB: PubMed Journal: Trop Med Health ISSN: 1348-8945
Results of urine filtering examination 2010-2011
| 2010 | 2011 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June | August | June | August | |||||||||||||
| Number of Subjects | Before 1st MDA | Number of Subjects | 8 weeks after 1st MDA | Number of Subjects | Before 2nd MDA | Number of Subjects | 8 weeks after 2nd MDA | |||||||||
| Egg positive number | Egg positive prevalence (95% CI) | Egg positive number | Egg positive prevalence (95% CI) | Egg positive number | Egg positive prevelence (95% CI) | Egg positive number | Egg positive prevalence (95% CI) | |||||||||
| Total | 242 | 83 | 34.3 (28.5-40.5) | 260 | 33 | 12.7** (9.2-17.3) | 315 | 46 | 14.6 (11.1-19.0) | 350 | 24 | 6.9** (4.6-10.0) | ||||
| Male | 108 | 46 | 42.6 (33.6-52.1) | 123 | 16 | 13.0** (8.1-20.2) | 152 | 25 | 16.4 (11.4-23.2) | 172 | 9 | 5.2** (2.8-9.7) | ||||
| Female | 134 | 37 | 27.6 (20.7-35.8) | 137 | 17 | 12.4 (8.3-20.0) | 163 | 21 | 12.9 (8.5-19.0) | 178 | 15 | 8.4 (5.1-13.5) | ||||
| Age group | 〜4 | Male | 5 | 3 | 60.0 (22.8-88.4) | 6 | 0 | 0.0* (0.0-39.5) | 11 | 3 | 27.3 (9.6-56.8) | 12 | 1 | 8.3 (1.5-35.7) | ||
| Female | 4 | 0 | 0.0 (0.0-49.5) | 4 | 0 | 0.0 (0.0-49.5) | - | 4 | 1 | 25.0 (4.5-70.3) | 6 | 1 | 16.7 (3.0-56.7) | |||
| Total | 9 | 3 | 33.3 (11.9-64.8) | 10 | 0 | 0.0* (0.0-28.2) | 15 | 4 | 26.7 (10.8-52.2) | 18 | 2 | 11.1 (3.1-33.1) | ||||
| 5〜9 | Male | 25 | 8 | 32.1 (17.1-51.8) | 26 | 0 | 0.0 (0.0-13.1) | 31 | 5 | 16.1 (7.0-32.8) | 32 | 2 | 6.3 (1.7-20.3) | |||
| Female | 29 | 10 | 34.5 (19.8-52.8) | 30 | 2 | 6.7** (1.7-20.3) | 29 | 6 | 20.7 (9.8-38.6) | 27 | 5 | 18.5 (8.1-36.9) | ||||
| Total | 54 | 18 | 33.4 (22.1-46.8) | 56 | 2 | 3.6** (1.0-12.2) | 60 | 11 | 18.3 (10.5-30.1) | 59 | 7 | 11.9 (5.8-22.7) | ||||
| 10〜14 | Male | 22 | 11 | 50 (30.6-69.4) | 24 | 3 | 12.5** (4.3-31.2) | 24 | 8 | 33.3 (17.9-53.5) | 21 | 3 | 14.3 (4.9-34.9) | |||
| Female | 26 | 7 | 26.9 (13.6-46.3) | 26 | 5 | 19.2 (8.4-38.1) | 28 | 7 | 25.0 (12.6-43.6) | 32 | 2 | 6.3* (1.7-20.3) | ||||
| Total | 48 | 18 | 37.5 (25.1-51.8) | 50 | 8 | 16.0* (8.3-28.7) | 52 | 15 | 28.8 (18.2-42.4) | 53 | 5 | 9.4* (4.1-20.4) | ||||
| 15〜19 | Male | 11 | 5 | 45.5 (21.1-72.2) | 14 | 3 | 21.4 (7.5-47.9) | 14 | 2 | 14.3 (4.0-40.2) | 17 | 0 | 0.0 (0.0-18.7) | |||
| Female | 10 | 3 | 30.0 (10.7-60.6) | 14 | 3 | 21.4 (7.5-47.9) | 14 | 4 | 28.6 (11.6-54.9) | 14 | 1 | 7.1 (1.3-31.8) | ||||
| Total | 21 | 8 | 38.1 (20.6-59.3) | 28 | 6 | 21.4 (10.1-39.7) | 28 | 6 | 21.4 (10.1-39.7) | 31 | 1 | 3.2* (0.6-16.4) | ||||
| 20〜29 | Male | 15 | 8 | 53.3 (29.9-75.4) | 19 | 4 | 21.1 (8.4-43.6) | 21 | 2 | 9.5 (2.6-29.2) | 23 | 2 | 8.7 (2.4-27.0) | |||
| Female | 25 | 11 | 44.0 (26.5-63.1) | 27 | 3 | 11.1** (3.8-28.3) | 30 | 1 | 3.3 (0.6-16.9) | 29 | 2 | 6.9 (1.9-22.2) | ||||
| Total | 40 | 19 | 47.5 (32.8-62.6) | 46 | 7 | 15.2 (7.5-28.4) | 51 | 3 | 5.9 (2.0-16.1) | 52 | 4 | 7.7 (3.0-18.3) | ||||
| 30〜39 | Male | 14 | 5 | 35.7 (16.2-61.5) | 16 | 4 | 25.0 (10.1-49.7) | 16 | 2 | 12.5 (3.5-36.3) | 18 | 1 | 5.6 (1.0-26.0) | |||
| Female | 15 | 5 | 33.3 (15.1-58.5) | 18 | 1 | 5.6* (1.0-26.0) | 18 | 1 | 5.6 (1.0-26.0) | 18 | 2 | 11.1 (3.1-33.1) | ||||
| Total | 29 | 10 | 34.5 (19.8-52.8) | 34 | 5 | 14.7 (6.4-30.3) | 34 | 3 | 8.8 (3.0-23.1) | 36 | 3 | 8.3 (2.8-22.0) | ||||
| 40〜 | Male | 16 | 6 | 37.5 (18.3-61.6) | 18 | 2 | 11.1 (3.1-33.1) | 24 | 3 | 12.5 (4.3-31.2) | 25 | 0 | 0.0 (0.0-13.6) | |||
| Female | 25 | 1 | 4.0 (0.7-19.8) | 18 | 3 | 16.7 (5.8-39.5) | 29 | 1 | 3.4 (0.6-17.4) | 27 | 2 | 7.4 (2.0-23.6) | ||||
| Total | 41 | 7 | 17.1 (8.5-31.4) | 36 | 5 | 13.9 (6.0-28.8) | 53 | 4 | 7.5 (2.9-18.0) | 52 | 2 | 3.8 (1.0-13.1) | ||||
(*p<0.05, **p<0.01)
Fig. 1Process of egg-positive rate among all participants 2010–2011
Fig. 2a Process of egg-positive rate by age group 2010–2011. b Process of egg-positive rate by age group 2010–2011
Fig. 3Analysis for the results of occult blood by urine strip tests
MDA Coverage Rate by Area in 2012
| Socio-demographic characteristics area | Proportional MDA attendance by area 2012 | ||
|---|---|---|---|
| Registered | Treated | Percentage coverage (%) | |
| Chisindo | 390 | 196 | 50.3 |
| Mtika | 331 | 284 | 85.8 |
| Mapiri | 296 | 192 | 64.9 |
| Chisaka | 376 | 200 | 53.2 |
| Total | 1393 | 772 | 55.4 |
Results of urine filtering examination 2013
| 2013 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| June | August | ||||||||
| Number of Subjects | Before MDA* | Number of Subjects | 8 weeks after MDA* | ||||||
| Egg positive number | Egg positive prevalence (95% CI) | Egg positive number | Egg positive prevalence (95% CI) | ||||||
| Total | 264 | 10 | 3.8 (2.1-6.9) | 211 | 2 | 0.9 (0.3-3.4) | |||
| Male | 99 | 6 | 6.1 (2.8-12.7) | 86 | 1 | 1.2 (0.2-6.4) | |||
| Female | 165 | 4 | 2.4 (0.9-6.1) | 125 | 1 | 0.8 (0.1-4.5) | |||
| Age group | 〜4 | Male | 14 | 1 | 7.1 (1.3-31.8) | 8 | 0 | 0.0 (0.0-32.9) | |
| Female | 20 | 2 | 10.0 (2.8-30.4) | 15 | 0 | 0.0 (0.0-20.7) | |||
| Total | 34 | 3 | 8.8 (3.0-23.1) | 23 | 0 | 0.0 (0.0-14.6) | |||
| 5〜9 | Male | 20 | 1 | 5.0 (0.9-23.9) | 22 | 0 | 0.0 (0.0-15.1) | ||
| Female | 19 | 0 | 0.0 (0.0-17.1) | 19 | 0 | 0.0 (0.0-17.1) | - | ||
| Total | 39 | 1 | 2.6 (0.4-13.3) | 41 | 0 | 0.0 (0.0-8.7) | |||
| 10〜14 | Male | 28 | 1 | 3.6 (0.6-17.9) | 22 | 0 | 0.0 (0.0-15.1) | ||
| Female | 26 | 1 | 3.8 (0.7-19.1) | 33 | 0 | 0.0 (0.0-10.6) | |||
| Total | 54 | 2 | 3.7 (1.0-12.7) | 55 | 0 | 0.0 (0.0-6.7) | |||
| 15〜19 | Male | 9 | 1 | 11.1 (2.0-43.9) | 8 | 1 | 12.5 (2.2-47.5) | ||
| Female | 22 | 0 | 0.0 (0.0-15.1) | 10 | 1 | 10.0 (1.8-40.8) | |||
| Total | 31 | 1 | 3.2 (0.6-16.4) | 18 | 2 | 11.1 (3.1-33.1) | |||
| 20〜29 | Male | 13 | 1 | 7.7 (1.4-33.6) | 15 | 0 | 0.0 (0.0-20.7) | ||
| Female | 32 | 1 | 3.1 (0.5-15.9) | 20 | 0 | 0.0 (0.0-16.4) | |||
| Total | 45 | 2 | 4.4 (1.2-15.0) | 35 | 0 | 0.0 (0.0-10.1) | |||
| 30〜39 | Male | 3 | 1 | 33.3 (6.1-79.5) | 2 | 0 | 0.0 (0.0-66.2) | ||
| Female | 12 | 0 | 0.0 (0.0-24.6) | 5 | 0 | 0.0 (0.0-43.9) | - | ||
| Total | 15 | 1 | 6.7 (1.2-30.1) | 7 | 0 | 0.0 (0.0-35.9) | |||
| 40〜 | Male | 12 | 0 | 0.0 (0.0-24.6) | 9 | 0 | 0.0 (0.0-30.3) | - | |
| Female | 34 | 2 | 5.9 (1.6-19.3) | 23 | 0 | 0.0 (0.0-14.6) | |||
| Total | 46 | 2 | 4.3 (1.2-14.7) | 32 | 0 | 0.0 (0.0-10.9) | |||
Fig. 4a Process of egg-positive rate by age group 2013. b Process of egg-positive rate by age group 2013